0001725160-21-000197.txt : 20211004 0001725160-21-000197.hdr.sgml : 20211004 20211004211510 ACCESSION NUMBER: 0001725160-21-000197 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211004 FILED AS OF DATE: 20211004 DATE AS OF CHANGE: 20211004 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Johnson David Michael CENTRAL INDEX KEY: 0001808098 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39263 FILM NUMBER: 211304950 MAIL ADDRESS: STREET 1: C/O ZENTALIS PHARMACEUTICALS, LLC STREET 2: 530 SEVENTH AVENUE, SUITE 2201 CITY: NEW YORK STATE: NY ZIP: 10018 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Zentalis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001725160 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 530 SEVENTH AVENUE, SUITE 2201 CITY: NEW YORK STATE: NY ZIP: 10018 BUSINESS PHONE: (212) 433-3791 MAIL ADDRESS: STREET 1: 530 SEVENTH AVENUE, SUITE 2201 CITY: NEW YORK STATE: NY ZIP: 10018 FORMER COMPANY: FORMER CONFORMED NAME: Zentalis Pharmaceuticals, LLC DATE OF NAME CHANGE: 20200107 FORMER COMPANY: FORMER CONFORMED NAME: Zeno Pharma, LLC DATE OF NAME CHANGE: 20171212 4 1 wf-form4_163339649177277.xml FORM 4 X0306 4 2021-10-04 0 0001725160 Zentalis Pharmaceuticals, Inc. ZNTL 0001808098 Johnson David Michael C/O ZENTALIS PHARMACEUTICALS, INC. 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018 1 0 0 0 Common Stock 2021-10-04 4 S 0 4892 65.9501 D 88963 D Common Stock 2021-10-04 4 S 0 7904 66.579 D 81059 D Common Stock 2021-10-04 4 S 0 100 67.20 D 80959 D The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $65.16 to $66.15. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $66.16 to $67.14. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. By: /s/ Melissa B. Epperly, Attorney-in-Fact for David M. Johnson 2021-10-04